Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy
Purpose: To determine the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in the setting of optic disc edema secondary to hematologic malignancies. Observations: The report features two patients (one male, one female) in their 70's with biopsy proven hematologic malignan...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993624001051 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850251612140863488 |
|---|---|
| author | Thomas P. Toohey Jake Shortt Nevin John Salmaan Al-Qureshi Sanjeewa S. Wickremasinghe |
| author_facet | Thomas P. Toohey Jake Shortt Nevin John Salmaan Al-Qureshi Sanjeewa S. Wickremasinghe |
| author_sort | Thomas P. Toohey |
| collection | DOAJ |
| description | Purpose: To determine the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in the setting of optic disc edema secondary to hematologic malignancies. Observations: The report features two patients (one male, one female) in their 70's with biopsy proven hematologic malignancies who subsequently developed optic disc edema. The patients were commenced on a trial of successive intravitreal Aflibercept 2mg/0.05mL therapy. The best corrected visual acuity for patient 1 improved from 20/50 oculus dexter (OD) and 20/80 oculus sinister (OS), to 20/20 OD (4 lines Early Treatment of Diabetic Retinopathy Study (ETDRS)) and 20/32 OS (4 lines ETDRS). Similarly, patient 2's best corrected visual acuity improved from 20/100 OU to 20/50 OD (3 lines ETDRS) and 20/40 OS (4 lines ETDRS) following initiation of treatment. In addition, optical coherence tomography imaging obtained before and after therapy demonstrated an improvement in both patient's optic disc edema and cystoid macular edema. Conclusions and importance: The findings of this report suggest that in patients with a known hematologic malignancy, optic disc edema and cystoid macular edema may be amenable to anti-VEGF treatment, especially if there are clinical and angiographic features of vascular endothelial growth factor overexpression. |
| format | Article |
| id | doaj-art-c122eae80db5465cb6d50dc0510791d2 |
| institution | OA Journals |
| issn | 2451-9936 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj-art-c122eae80db5465cb6d50dc0510791d22025-08-20T01:57:51ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362024-12-013610209510.1016/j.ajoc.2024.102095Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancyThomas P. Toohey0Jake Shortt1Nevin John2Salmaan Al-Qureshi3Sanjeewa S. Wickremasinghe4Eastern Health, 5 Arnold Street, Box Hill, VIC, 3128, Australia; Corresponding author.Monash Haematology, Monash Health, 246 Clayton Road, Clayton, VIC, 3168, Australia; Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Wellington Rd, Clayton, VIC, 3800, AustraliaDepartment of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Wellington Rd, Clayton, VIC, 3800, Australia; Department of Neurology, Monash Health, 246 Clayton Road, Clayton, VIC, 3168, AustraliaCentre for Eye Research Australia (CERA), Level 7/32 Gisborne St, East Melbourne VIC 3002, Australia; Royal Victorian Eye and Ear Hospital, 32 Gisborne Street, East Melbourne VIC 3002, AustraliaCentre for Eye Research Australia (CERA), Level 7/32 Gisborne St, East Melbourne VIC 3002, Australia; Royal Victorian Eye and Ear Hospital, 32 Gisborne Street, East Melbourne VIC 3002, AustraliaPurpose: To determine the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in the setting of optic disc edema secondary to hematologic malignancies. Observations: The report features two patients (one male, one female) in their 70's with biopsy proven hematologic malignancies who subsequently developed optic disc edema. The patients were commenced on a trial of successive intravitreal Aflibercept 2mg/0.05mL therapy. The best corrected visual acuity for patient 1 improved from 20/50 oculus dexter (OD) and 20/80 oculus sinister (OS), to 20/20 OD (4 lines Early Treatment of Diabetic Retinopathy Study (ETDRS)) and 20/32 OS (4 lines ETDRS). Similarly, patient 2's best corrected visual acuity improved from 20/100 OU to 20/50 OD (3 lines ETDRS) and 20/40 OS (4 lines ETDRS) following initiation of treatment. In addition, optical coherence tomography imaging obtained before and after therapy demonstrated an improvement in both patient's optic disc edema and cystoid macular edema. Conclusions and importance: The findings of this report suggest that in patients with a known hematologic malignancy, optic disc edema and cystoid macular edema may be amenable to anti-VEGF treatment, especially if there are clinical and angiographic features of vascular endothelial growth factor overexpression.http://www.sciencedirect.com/science/article/pii/S2451993624001051Macular edemaOptic disc edemaVascular endothelial growth factor |
| spellingShingle | Thomas P. Toohey Jake Shortt Nevin John Salmaan Al-Qureshi Sanjeewa S. Wickremasinghe Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy American Journal of Ophthalmology Case Reports Macular edema Optic disc edema Vascular endothelial growth factor |
| title | Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy |
| title_full | Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy |
| title_fullStr | Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy |
| title_full_unstemmed | Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy |
| title_short | Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy |
| title_sort | intravitreal anti vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy |
| topic | Macular edema Optic disc edema Vascular endothelial growth factor |
| url | http://www.sciencedirect.com/science/article/pii/S2451993624001051 |
| work_keys_str_mv | AT thomasptoohey intravitrealantivascularendothelialgrowthfactortherapyinthetreatmentofvisionlossassociatedwithhematologicmalignancy AT jakeshortt intravitrealantivascularendothelialgrowthfactortherapyinthetreatmentofvisionlossassociatedwithhematologicmalignancy AT nevinjohn intravitrealantivascularendothelialgrowthfactortherapyinthetreatmentofvisionlossassociatedwithhematologicmalignancy AT salmaanalqureshi intravitrealantivascularendothelialgrowthfactortherapyinthetreatmentofvisionlossassociatedwithhematologicmalignancy AT sanjeewaswickremasinghe intravitrealantivascularendothelialgrowthfactortherapyinthetreatmentofvisionlossassociatedwithhematologicmalignancy |